Antique Broking has maintained a ‘Buy’ rating on Alembic Pharmaceuticals, raising its target price to ₹1,275 from ₹1,154, citing strong growth momentum in the US business and stable domestic execution. The stock was trading at ₹1,111.66 in the latest session.
The brokerage highlighted that Alembic’s US business is witnessing accelerated growth, which remains a key driver, while domestic execution will continue to be a strategic focus. The management is also actively addressing execution challenges in the specialty segment.
Antique expects 4–5 new product launches in the US in Q2FY26, including gEntresto, which could support 10–15% growth in FY26E. Additionally, the brokerage noted that operating leverage and a well-diversified growth engine are seen as strong positives for the company.
FY26E and FY27E estimates remain largely unchanged as per the brokerage, indicating a stable outlook ahead.
Disclaimer: The views and investment recommendations expressed in this article are those of the brokerage firm quoted. These do not represent the views of Business Upturn. Investors are advised to consult certified financial advisers before making any investment decisions.
